Aura Biosciences: CoMpass Phase 3 topline na ngayon ay inaasahan sa Q4 2027

Na-update ng kumpanya ang gabay nito sa Phase 3 CoMpass trial, na ngayon ay inaasahan ang pagkumpleto ng enrollment sa 2026 at topline data para sa 15-buwan na primary endpoint sa Q4 2027. Pinapalitan nito ang mga naunang open-ended na timeline at sumasalamin sa mas mabagal kaysa sa inaasahang enrollment dahil sa kinakailangan ng dokumentadong paglaki ng tumor at mga hamon sa global site activation.

Mahahalagang fact

Na-file: Nob 13, 2025, 12:05 PM
Kaganapan: Pagbabago sa trial registry
Direksyon: Neutral
Kumpanya: AURAAura Biosciences
Asset: bel-sar
Pinagmulan: SEC 8-K
Kumpiyansa: May source
pangunahing endpoint: 15-buwan
target ng enrollment: ~100 pasyente

Sipi mula sa source

EX-99.1 2 aura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, MA – November 13, 2025 – Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2025, and provided recent business

SEC 8-K